Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

NCT05799248 is registered in ClinicalTrials.gov with MidLantic Urology as lead sponsor.

NCT NCT05799248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05799248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Lead sponsor
MidLantic Urology
Phase
Phase 3
Overall status
Unknown status
Start date
April 27, 2023
Completion date
May 28, 2024
Enrollment
113 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer